<DOC>
	<DOCNO>NCT01754727</DOCNO>
	<brief_summary>The purpose study assess proportion AS patient achieve treatment response adalimumab therapy .</brief_summary>
	<brief_title>Impact Adalimumab ( Humira® ) Therapy Selected Health Care Resource Utilization Sick Leave Patients With Ankylosing Spondylitis Clinical Practice</brief_title>
	<detailed_description>This post-marketing observational study ( PMOS ) perform multi-country , multi-center , single-arm format . Data collect prospectively retrospectively . Adult patient diagnosis AS assign treatment adalimumab ( Humira® ) eligible participation . Each patient include study observe his/her adalimumab treatment maximum 12 month period . During period four follow-up visit plan observation patient documentation data . Ideally , visit perform approximately 3 ( V1 ) , 6 ( V2 ) , 9 ( V3 ) 12 ( V4 ) month baseline visit ( V0 ) .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Had ankylose spondylitis ( AS ) eligible start and/or continue adalimumab therapy accord local product label prescription guideline , Had start adalimumab therapy one ( 1 ) month prior study enrollment Had negative result tuberculosis ( TB ) screen test receive tuberculosis prophylaxis per local guideline Provided write Authorization investigator use and/or disclose personal and/or health data , Informed Consent request Local Regulations Had contraindication treatment adalimumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Post-marketing observational study ( PMOS )</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira®</keyword>
</DOC>